7.61
-0.03(-0.39%)
Currency In USD
| Previous Close | 7.64 |
| Open | 7.71 |
| Day High | 7.88 |
| Day Low | 7.51 |
| 52-Week High | 29.61 |
| 52-Week Low | 5.9 |
| Volume | 1.41M |
| Average Volume | 1.79M |
| Market Cap | 558.71M |
| PE | -7.53 |
| EPS | -1.01 |
| Moving Average 50 Days | 7.51 |
| Moving Average 200 Days | 11.62 |
| Change | -0.03 |
If you invested $1000 in Arvinas, Inc. (ARVN) since IPO date, it would be worth $474.14 as of September 17, 2025 at a share price of $7.61. Whereas If you bought $1000 worth of Arvinas, Inc. (ARVN) shares 5 years ago, it would be worth $283.74 as of September 17, 2025 at a share price of $7.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
GlobeNewswire Inc.
2 hours ago
Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant Additional cost optimization measures expected to realize total annual savings of more than $100 million compared to FY 2024 Board auth
Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
GlobeNewswire Inc.
Aug 08, 2025 8:05 PM GMT
– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – Vepdegestrant is the first PROteolysis TArgeting Chime
Arvinas to Report Second Quarter 2025 Financial Results on August 6, 2025
GlobeNewswire Inc.
Jul 30, 2025 8:05 PM GMT
NEW HAVEN, Conn., July 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review financial resu